FOVEPTA

This brand name is authorized in Tunisia, Turkey

Active ingredients

The drug FOVEPTA contains one active pharmaceutical ingredient (API):

1 Human hepatitis B immunoglobulin
UNII XII270YC6M - HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN

Human hepatitis B immunoglobulin solution for infusion contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBs). It is used for the immunoprophylaxis of hepatitis B and the prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure.

Read about Human hepatitis B immunoglobulin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J06BB04 Hepatitis B immunoglobulin J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 8153101H
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699535980530

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.